Financials data is unavailable for this security.
View more
Year on year Novartis AG grew revenues 8.91% from 51.72bn to 56.33bn. In addition the company has reduced the cost of goods sold as a percent of sales, selling, general and administrative expenses as a percent of sales and interest paid as a percent of sales. These improvements contributed to 17.11% net income growth from 11.94bn to 13.98bn.
| Gross margin | 75.82% |
|---|---|
| Net profit margin | 24.79% |
| Operating margin | 31.00% |
| Return on assets | 13.10% |
|---|---|
| Return on equity | 31.01% |
| Return on investment | 17.82% |
More ▼
Cash flow in USDView more
In 2025, Novartis AG did not generate a significant amount of cash. However, the company earned 19.14bn from its operations for a Cash Flow Margin of 33.99%. In addition the company used 4.88bn on investing activities and also paid 14.87bn in financing cash flows.
| Cash flow per share | 7.38 |
|---|---|
| Price/Cash flow per share | 18.84 |
| Book value per share | 18.50 |
|---|---|
| Tangible book value per share | -3.55 |
More ▼
Balance sheet in USDView more
| Current ratio | 1.12 |
|---|---|
| Quick ratio | 0.8868 |
| Total debt/total equity | 0.7669 |
|---|---|
| Total debt/total capital | 0.4318 |
More ▼
Growth rates in USD
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 21.04% and 21.90%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth ranked highest relative to its industry peers, while earnings per share growth is in-line with the industry average.
| Div yield(5 year avg) | 3.82% |
|---|---|
| Div growth rate (5 year) | 6.62% |
| Payout ratio (TTM) | 64.08% |
| EPS growth(5 years) | 15.26 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 21.92 |
More ▼
